Memphis
Gold rises on renewed US stimulus hope, dollar falls
Spot gold rose 0.3 percent to $1,910.56 an ounce at 3:37pm, New York time, after falling as much as 0.5 percent. Gold rose on renewed optimism for a preelection aid package in the U.S., while the dollar fell to a one-week low. House Speaker Nancy Pelosi said a bill for a compromise stimulus package is being written as she awaits a key phone call with Treasury Secretary Steven Mnuchin. Senate Majority Leader Mitch McConnell said his chamber would take up a comprehensive coronavirus package if an accord is struck. The Bloomberg Dollar Spot Index headed for the third straight decline. Pelosi said in a Bloomberg Television interview that while there are areas where more work is required to get a compromise, she was pleased with the Trump administration’s latest position on coronavirus testing ...
Lyon set deadline for Memphis Depay’s departure
Olympique Lyonnais have set Barcelona an ultimatum on signing their forward Memphis Depay this transfer window, as per Diario AS. The report cites how Lyon president Jean-Michel Aulas has told French media outlet Telefoot: “I think I will tell the players that all those who did not leave on Friday will remain at Lyon. As of Friday there will be no more departures.” It is reported how he is referencing both Memphis and midfielder Houssem Aouar – who has been linked with a switch to Arsenal. The Blaugrana are keen on a move for Memphis but it remains unlikely that they will be able to finance a deal, despite clearing Arturo Vidal, Ivan Rakitic and Luis Suarez from their wage bill. Memphis, 26, netted 11 goals across his last 18 matches for the Dutch national side and has also developed into ...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
